GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound
NCT07251803 · Recruiting
Last updated 2026-05-28This clinical trial is testing how fasting before taking a GLP1 medication affects stomach emptying in people with delayed stomach emptying.
What this study is testing ClinicalTrials.gov NCT07251803 ↗
Description as written by the study sponsor.
This study will enroll patients 18 years and older who are taking a GLP-1/GIP medication and 1) are scheduled for elective surgery and meet ASA fasting guidelines (nothing by mouth for at least 8 hours prior), or 2) scheduled elective colonoscopy and have been on a clear liquid diet for at least 24 hours prior. Participants will have a gastric ultrasound prior to surgery to measure any retained gastric contents. The purpose of this study is to determine if people taking GLP-1 receptor agonists and who fast normally are at an equal risk for having retained gastric contents after appropriately fasting for surgery, compared to patients who are on a liquid only diet for 24 hours prior to surgery.
Treatments tested
- Gastric Ultrasound Diagnostic test
All participants will undergo a gastric ultrasound in the preoperative area prior to their scheduled procedure. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position (RLD), and the above procedure will be repeated. The measurement of gastric antral cross-sectional area while in the RLD position will be recorded and used to calculate the gastric volume.
| Main thing measured | Pre-operative gastric volume per unit of weight (ml/kg) as assessed by gastric ultrasound. |
|---|---|
| Sponsor | Medical University of South Carolina |
| Conditions studied | Gastric Retention |
| GLP-1 drugs | — |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07251803 ↗